Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 86

1.

Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study.

Jakimovski D, Zivadinov R, Ramanthan M, Hagemeier J, Weinstock-Guttman B, Tomic D, Kropshofer H, Fuchs TA, Barro C, Leppert D, Yaldizli Ö, Kuhle J, Benedict RH.

Mult Scler. 2019 Oct 15:1352458519881428. doi: 10.1177/1352458519881428. [Epub ahead of print]

PMID:
31610732
2.

Targeting Iron Dyshomeostasis for Treatment of Neurodegenerative Disorders.

Bergsland N, Tavazzi E, Schweser F, Jakimovski D, Hagemeier J, Dwyer MG, Zivadinov R.

CNS Drugs. 2019 Sep 25. doi: 10.1007/s40263-019-00668-6. [Epub ahead of print]

PMID:
31556017
3.

Atrophied Brain T2 Lesion Volume at MRI Is Associated with Disability Progression and Conversion to Secondary Progressive Multiple Sclerosis.

Genovese AV, Hagemeier J, Bergsland N, Jakimovski D, Dwyer MG, Ramasamy DP, Lizarraga AA, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

Radiology. 2019 Nov;293(2):424-433. doi: 10.1148/radiol.2019190306. Epub 2019 Sep 24.

PMID:
31549947
4.

Teriflunomide's effect on humoral response to Epstein-Barr virus and development of cortical gray matter pathology in multiple sclerosis.

Zivadinov R, Ramanathan M, Hagemeier J, Bergsland N, Ramasamy DP, Durfee J, Kolb C, Weinstock-Guttman B.

Mult Scler Relat Disord. 2019 Sep 9;36:101388. doi: 10.1016/j.msard.2019.101388. [Epub ahead of print]

PMID:
31525628
5.

Serum neurofilament light chain levels associations with gray matter pathology: a 5-year longitudinal study.

Jakimovski D, Kuhle J, Ramanathan M, Barro C, Tomic D, Hagemeier J, Kropshofer H, Bergsland N, Leppert D, Dwyer MG, Michalak Z, Benedict RHB, Weinstock-Guttman B, Zivadinov R.

Ann Clin Transl Neurol. 2019 Sep;6(9):1757-1770. doi: 10.1002/acn3.50872. Epub 2019 Aug 22.

6.

Cholesterol and neurodegeneration: longitudinal changes in serum cholesterol biomarkers are associated with new lesions and gray matter atrophy in multiple sclerosis over 5 years of follow-up.

Murali N, Browne RW, Fellows Maxwell K, Bodziak ML, Jakimovski D, Hagemeier J, Bergsland N, Weinstock-Guttman B, Zivadinov R, Ramanathan M.

Eur J Neurol. 2019 Aug 1. doi: 10.1111/ene.14055. [Epub ahead of print]

PMID:
31369181
7.

Cumulative gadodiamide administration leads to brain gadolinium deposition in early MS.

Zivadinov R, Bergsland N, Hagemeier J, Ramasamy DP, Dwyer MG, Schweser F, Kolb C, Weinstock-Guttman B, Hojnacki D.

Neurology. 2019 Aug 6;93(6):e611-e623. doi: 10.1212/WNL.0000000000007892. Epub 2019 Jul 8.

PMID:
31285398
8.

No association between variations in extracranial venous anatomy and clinical outcomes in multiple sclerosis patients over 5 years.

Gandhi S, Marr K, Mancini M, Caprio MG, Jakimovski D, Chandra A, Hagemeier J, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

BMC Neurol. 2019 Jun 11;19(1):121. doi: 10.1186/s12883-019-1350-2.

9.

Ventral posterior substantia nigra iron increases over 3 years in Parkinson's disease.

Bergsland N, Zivadinov R, Schweser F, Hagemeier J, Lichter D, Guttuso T Jr.

Mov Disord. 2019 Jul;34(7):1006-1013. doi: 10.1002/mds.27730. Epub 2019 Jun 10.

PMID:
31180615
10.

Oxysterols and apolipoproteins in multiple sclerosis: a 5 year follow-up study.

Fellows Maxwell K, Bhattacharya S, Bodziak ML, Jakimovski D, Hagemeier J, Browne RW, Weinstock-Guttman B, Zivadinov R, Ramanathan M.

J Lipid Res. 2019 Jul;60(7):1190-1198. doi: 10.1194/jlr.M089664. Epub 2019 May 13.

PMID:
31085627
11.

Aging and Brain Atrophy in Multiple Sclerosis.

Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Paunkoski I, Ramasamy DP, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

J Neuroimaging. 2019 Jul;29(4):527-535. doi: 10.1111/jon.12625. Epub 2019 May 10.

PMID:
31074192
12.

Marijuana Use by Patients with Multiple Sclerosis.

Gupta S, Fellows K, Weinstock-Guttman B, Hagemeier J, Zivadinov R, Ramanathan M.

Int J MS Care. 2019 Mar-Apr;21(2):57-62. doi: 10.7224/1537-2073.2017-112.

13.

Effect of Teriflunomide and Dimethyl Fumarate on Cortical Atrophy and Leptomeningeal Inflammation in Multiple Sclerosis: A Retrospective, Observational, Case-Control Pilot Study.

Zivadinov R, Bergsland N, Carl E, Ramasamy DP, Hagemeier J, Dwyer MG, Lizarraga AA, Kolb C, Hojnacki D, Weinstock-Guttman B.

J Clin Med. 2019 Mar 12;8(3). pii: E344. doi: 10.3390/jcm8030344.

14.

A Serial 10-Year Follow-Up Study of Atrophied Brain Lesion Volume and Disability Progression in Patients with Relapsing-Remitting MS.

Zivadinov R, Horakova D, Bergsland N, Hagemeier J, Ramasamy DP, Uher T, Vaneckova M, Havrdova E, Dwyer MG.

AJNR Am J Neuroradiol. 2019 Mar;40(3):446-452. doi: 10.3174/ajnr.A5987. Epub 2019 Feb 28.

PMID:
30819766
15.

Dietary and lifestyle factors in multiple sclerosis progression: results from a 5-year longitudinal MRI study.

Jakimovski D, Weinstock-Guttman B, Gandhi S, Guan Y, Hagemeier J, Ramasamy DP, Fuchs TA, Browne RW, Bergsland N, Dwyer MG, Ramanathan M, Zivadinov R.

J Neurol. 2019 Apr;266(4):866-875. doi: 10.1007/s00415-019-09208-0. Epub 2019 Feb 13.

PMID:
30758665
16.

Brain Atrophy Is Associated with Disability Progression in Patients with MS followed in a Clinical Routine.

Ghione E, Bergsland N, Dwyer MG, Hagemeier J, Jakimovski D, Paunkoski I, Ramasamy DP, Silva D, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B, Zivadinov R.

AJNR Am J Neuroradiol. 2018 Dec;39(12):2237-2242. doi: 10.3174/ajnr.A5876. Epub 2018 Nov 22.

17.

Assessment of mesoscopic properties of deep gray matter iron through a model-based simultaneous analysis of magnetic susceptibility and R2* - A pilot study in patients with multiple sclerosis and normal controls.

Taege Y, Hagemeier J, Bergsland N, Dwyer MG, Weinstock-Guttman B, Zivadinov R, Schweser F.

Neuroimage. 2019 Feb 1;186:308-320. doi: 10.1016/j.neuroimage.2018.11.011. Epub 2018 Nov 14.

PMID:
30445148
18.

Walking disability measures in multiple sclerosis patients: Correlations with MRI-derived global and microstructural damage.

Jakimovski D, Weinstock-Guttman B, Hagemeier J, Vaughn CB, Kavak KS, Gandhi S, Bennett SE, Fuchs TA, Bergsland N, Dwyer MG, Benedict RHB, Zivadinov R.

J Neurol Sci. 2018 Oct 15;393:128-134. doi: 10.1016/j.jns.2018.08.020. Epub 2018 Aug 23.

PMID:
30165291
19.

Abnormal venous postural control: multiple sclerosis-specific change related to gray matter pathology or age-related neurodegenerative phenomena?

Jakimovski D, Topolski M, Kimura K, Marr K, Gandhi S, Ramasamy DP, Bergsland N, Hagemeier J, Weinstock-Guttman B, Zivadinov R.

Clin Auton Res. 2019 Jun;29(3):329-338. doi: 10.1007/s10286-018-0555-6. Epub 2018 Aug 17.

PMID:
30120624
20.

Hypertension and heart disease are associated with development of brain atrophy in multiple sclerosis: a 5-year longitudinal study.

Jakimovski D, Gandhi S, Paunkoski I, Bergsland N, Hagemeier J, Ramasamy DP, Hojnacki D, Kolb C, Benedict RHB, Weinstock-Guttman B, Zivadinov R.

Eur J Neurol. 2019 Jan;26(1):87-e8. doi: 10.1111/ene.13769. Epub 2018 Sep 3.

PMID:
30103277
21.

Multimodal Imaging of Retired Professional Contact Sport Athletes Does Not Provide Evidence of Structural and Functional Brain Damage.

Zivadinov R, Polak P, Schweser F, Bergsland N, Hagemeier J, Dwyer MG, Ramasamy DP, Baker JG, Leddy JJ, Willer BS.

J Head Trauma Rehabil. 2018 Sep/Oct;33(5):E24-E32. doi: 10.1097/HTR.0000000000000422.

22.

Five-Year Longitudinal Study of Neck Vessel Cross-Sectional Area in Multiple Sclerosis.

Pelizzari L, Jakimovski D, Laganà MM, Bergsland N, Hagemeier J, Baselli G, Weinstock-Guttman B, Zivadinov R.

AJNR Am J Neuroradiol. 2018 Sep;39(9):1703-1709. doi: 10.3174/ajnr.A5738. Epub 2018 Jul 26.

23.

Brain Iron at Quantitative MRI Is Associated with Disability in Multiple Sclerosis.

Zivadinov R, Tavazzi E, Bergsland N, Hagemeier J, Lin F, Dwyer MG, Carl E, Kolb C, Hojnacki D, Ramasamy D, Durfee J, Weinstock-Guttman B, Schweser F.

Radiology. 2018 Nov;289(2):487-496. doi: 10.1148/radiol.2018180136. Epub 2018 Jul 17.

PMID:
30015589
24.

Altered nuclei-specific thalamic functional connectivity patterns in multiple sclerosis and their associations with fatigue and cognition.

Lin F, Zivadinov R, Hagemeier J, Weinstock-Guttman B, Vaughn C, Gandhi S, Jakimovski D, Hulst HE, Benedict RH, Bergsland N, Fuchs T, Dwyer MG.

Mult Scler. 2019 Aug;25(9):1243-1254. doi: 10.1177/1352458518788218. Epub 2018 Jul 13.

PMID:
30004291
25.

The Effect of Glatiramer Acetate on Retinal Nerve Fiber Layer Thickness in Patients with Relapsing-Remitting Multiple Sclerosis: A Longitudinal Optical Coherence Tomography Study.

Zivadinov R, Tavazzi E, Hagemeier J, Carl E, Hojnacki D, Kolb C, Weinstock-Guttman B.

CNS Drugs. 2018 Aug;32(8):763-770. doi: 10.1007/s40263-018-0521-9.

PMID:
29767815
26.

Effect of teriflunomide on gray and white matter brain pathology in multiple sclerosis using volumetric and diffusion-tensor imaging MRI measures.

Zivadinov R, Bergsland N, Hagemeier J, Carl E, Kolb H, Hojnacki D, Weinstock-Guttman B.

J Neurol Sci. 2018 May 15;388:175-181. doi: 10.1016/j.jns.2018.03.028. Epub 2018 Mar 17.

PMID:
29627017
27.

Effect of switching from glatiramer acetate 20 mg/daily to glatiramer acetate 40 mg three times a week on gray and white matter pathology in subjects with relapsing multiple sclerosis: A longitudinal DTI study.

Zivadinov R, Bergsland N, Hagemeier J, Tavazzi E, Ramasamy DP, Durfee J, Cherneva M, Carl E, Carl J, Kolb C, Hojnacki D, Weinstock-Guttman B.

J Neurol Sci. 2018 Apr 15;387:152-156. doi: 10.1016/j.jns.2018.02.023. Epub 2018 Feb 10.

PMID:
29571854
28.

Establishing pathological cut-offs for lateral ventricular volume expansion rates.

Dwyer MG, Hagemeier J, Bergsland N, Horakova D, Korn JR, Khan N, Uher T, Medin J, Silva D, Vaneckova M, Havrdova EK, Zivadinov R.

Neuroimage Clin. 2018 Feb 7;18:494-501. doi: 10.1016/j.nicl.2018.02.009. eCollection 2018.

29.

Evaluation of Leptomeningeal Contrast Enhancement Using Pre-and Postcontrast Subtraction 3D-FLAIR Imaging in Multiple Sclerosis.

Zivadinov R, Ramasamy DP, Hagemeier J, Kolb C, Bergsland N, Schweser F, Dwyer MG, Weinstock-Guttman B, Hojnacki D.

AJNR Am J Neuroradiol. 2018 Apr;39(4):642-647. doi: 10.3174/ajnr.A5541. Epub 2018 Feb 8.

30.

Substantia Nigra Free Water Increases Longitudinally in Parkinson Disease.

Guttuso T Jr, Bergsland N, Hagemeier J, Lichter DG, Pasternak O, Zivadinov R.

AJNR Am J Neuroradiol. 2018 Mar;39(3):479-484. doi: 10.3174/ajnr.A5545. Epub 2018 Feb 1.

31.

Effect of dimethyl fumarate on gray and white matter pathology in subjects with relapsing multiple sclerosis: a longitudinal study.

Zivadinov R, Hagemeier J, Bergsland N, Tavazzi E, Weinstock-Guttman B.

Eur J Neurol. 2018 Mar;25(3):584-e36. doi: 10.1111/ene.13562.

PMID:
29316038
32.

Lower Arterial Cross-Sectional Area of Carotid and Vertebral Arteries and Higher Frequency of Secondary Neck Vessels Are Associated with Multiple Sclerosis.

Belov P, Jakimovski D, Krawiecki J, Magnano C, Hagemeier J, Pelizzari L, Weinstock-Guttman B, Zivadinov R.

AJNR Am J Neuroradiol. 2018 Jan;39(1):123-130. doi: 10.3174/ajnr.A5469. Epub 2017 Dec 7.

33.

Neck Vessel Cross-Sectional Area Measured with MRI: Scan-Rescan Reproducibility for Longitudinal Evaluations.

Pelizzari L, Laganà MM, Jakimovski D, Bergsland N, Hagemeier J, Baselli G, Zivadinov R.

J Neuroimaging. 2018 Jan;28(1):48-56. doi: 10.1111/jon.12488. Epub 2017 Dec 4.

34.

Iron-related gene variants and brain iron in multiple sclerosis and healthy individuals.

Hagemeier J, Ramanathan M, Schweser F, Dwyer MG, Lin F, Bergsland N, Weinstock-Guttman B, Zivadinov R.

Neuroimage Clin. 2017 Nov 8;17:530-540. doi: 10.1016/j.nicl.2017.11.003. eCollection 2018.

35.

Mapping of thalamic magnetic susceptibility in multiple sclerosis indicates decreasing iron with disease duration: A proposed mechanistic relationship between inflammation and oligodendrocyte vitality.

Schweser F, Raffaini Duarte Martins AL, Hagemeier J, Lin F, Hanspach J, Weinstock-Guttman B, Hametner S, Bergsland N, Dwyer MG, Zivadinov R.

Neuroimage. 2018 Feb 15;167:438-452. doi: 10.1016/j.neuroimage.2017.10.063. Epub 2017 Oct 31.

36.

Effect of teriflunomide on cortex-basal ganglia-thalamus (CxBGTh) circuit glutamatergic dysregulation in the Theiler's Murine Encephalomyelitis Virus mouse model of multiple sclerosis.

Modica CM, Schweser F, Sudyn ML, Bertolino N, Preda M, Polak P, Siebert DM, Krawiecki JC, Sveinsson M, Hagemeier J, Dwyer MG, Pol S, Zivadinov R.

PLoS One. 2017 Aug 10;12(8):e0182729. doi: 10.1371/journal.pone.0182729. eCollection 2017.

37.

Centralized and Local Color Doppler Ultrasound Reading Agreement for Diagnosis of the Chronic Cerebrospinal Venous Insufficiency in Patients with Multiple Sclerosis.

Caprio MG, Marr K, Gandhi S, Jakimovski D, Hagemeier J, Weinstock-Guttman B, Zivadinov R, Mancini M.

Curr Neurovasc Res. 2017;14(3):266-273. doi: 10.2174/1567202614666170718095203.

38.

Olfactory identification deficit predicts white matter tract impairment in Alzheimer's disease.

Woodward MR, Dwyer MG, Bergsland N, Hagemeier J, Zivadinov R, Benedict RH, Szigeti K.

Psychiatry Res Neuroimaging. 2017 Aug 30;266:90-95. doi: 10.1016/j.pscychresns.2017.06.004. Epub 2017 Jun 9.

39.

Changes of deep gray matter magnetic susceptibility over 2 years in multiple sclerosis and healthy control brain.

Hagemeier J, Zivadinov R, Dwyer MG, Polak P, Bergsland N, Weinstock-Guttman B, Zalis J, Deistung A, Reichenbach JR, Schweser F.

Neuroimage Clin. 2017 Apr 13;18:1007-1016. doi: 10.1016/j.nicl.2017.04.008. eCollection 2018.

40.

Methods for the computation of templates from quantitative magnetic susceptibility maps (QSM): Toward improved atlas- and voxel-based analyses (VBA).

Hanspach J, Dwyer MG, Bergsland NP, Feng X, Hagemeier J, Bertolino N, Polak P, Reichenbach JR, Zivadinov R, Schweser F.

J Magn Reson Imaging. 2017 Nov;46(5):1474-1484. doi: 10.1002/jmri.25671. Epub 2017 Mar 6.

41.

An improved FSL-FIRST pipeline for subcortical gray matter segmentation to study abnormal brain anatomy using quantitative susceptibility mapping (QSM).

Feng X, Deistung A, Dwyer MG, Hagemeier J, Polak P, Lebenberg J, Frouin F, Zivadinov R, Reichenbach JR, Schweser F.

Magn Reson Imaging. 2017 Jun;39:110-122. doi: 10.1016/j.mri.2017.02.002. Epub 2017 Feb 7.

42.

Leptomeningeal contrast enhancement is associated with progression of cortical atrophy in MS: A retrospective, pilot, observational longitudinal study.

Zivadinov R, Ramasamy DP, Vaneckova M, Gandhi S, Chandra A, Hagemeier J, Bergsland N, Polak P, Benedict RH, Hojnacki D, Weinstock-Guttman B.

Mult Scler. 2017 Sep;23(10):1336-1345. doi: 10.1177/1352458516678083. Epub 2016 Nov 4.

PMID:
27811339
43.

Interdependence of oxysterols with cholesterol profiles in multiple sclerosis.

Mukhopadhyay S, Fellows K, Browne RW, Khare P, Krishnan Radhakrishnan S, Hagemeier J, Weinstock-Guttman B, Zivadinov R, Ramanathan M.

Mult Scler. 2017 May;23(6):792-801. doi: 10.1177/1352458516666187. Epub 2016 Sep 28.

44.

Odor identification deficit in mild cognitive impairment and Alzheimer's disease is associated with hippocampal and deep gray matter atrophy.

Hagemeier J, Woodward MR, Rafique UA, Amrutkar CV, Bergsland N, Dwyer MG, Benedict R, Zivadinov R, Szigeti K.

Psychiatry Res Neuroimaging. 2016 Sep 30;255:87-93. doi: 10.1016/j.pscychresns.2016.08.003. Epub 2016 Aug 15.

PMID:
27567325
45.

Cerebral Microbleeds in Multiple Sclerosis Evaluated on Susceptibility-weighted Images and Quantitative Susceptibility Maps: A Case-Control Study.

Zivadinov R, Ramasamy DP, Benedict RR, Polak P, Hagemeier J, Magnano C, Dwyer MG, Bergsland N, Bertolino N, Weinstock-Guttman B, Kolb C, Hojnacki D, Utriainen D, Haacke EM, Schweser F.

Radiology. 2016 Dec;281(3):884-895. Epub 2016 Jun 16.

PMID:
27308776
46.

Internal Jugular Vein Cross-Sectional Area and Cerebrospinal Fluid Pulsatility in the Aqueduct of Sylvius: A Comparative Study between Healthy Subjects and Multiple Sclerosis Patients.

Beggs CB, Magnano C, Belov P, Krawiecki J, Ramasamy DP, Hagemeier J, Zivadinov R.

PLoS One. 2016 May 2;11(5):e0153960. doi: 10.1371/journal.pone.0153960. eCollection 2016.

47.

Effect of natalizumab on brain atrophy and disability progression in multiple sclerosis patients over 5 years.

Zivadinov R, Hojnacki D, Bergsland N, Kennedy C, Hagemeier J, Melia R, Ramasamy DP, Durfee J, Carl E, Dwyer MG, Weinstock-Guttman B.

Eur J Neurol. 2016 Jun;23(6):1101-9. doi: 10.1111/ene.12992. Epub 2016 Mar 21.

PMID:
26998905
48.

Age-related brain atrophy may be mitigated by internal jugular vein enlargement in male individuals without neurologic disease.

Belov P, Magnano C, Krawiecki J, Hagemeier J, Bergsland N, Beggs C, Zivadinov R.

Phlebology. 2017 Mar;32(2):125-134. doi: 10.1177/0268355516633610. Epub 2016 Jul 9.

PMID:
26911619
49.

Internal Jugular Vein Cross-Sectional Area Enlargement Is Associated with Aging in Healthy Individuals.

Magnano C, Belov P, Krawiecki J, Hagemeier J, Beggs C, Zivadinov R.

PLoS One. 2016 Feb 19;11(2):e0149532. doi: 10.1371/journal.pone.0149532. eCollection 2016.

50.

A serial 10-year follow-up study of brain atrophy and disability progression in RRMS patients.

Zivadinov R, Uher T, Hagemeier J, Vaneckova M, Ramasamy DP, Tyblova M, Bergsland N, Seidl Z, Dwyer MG, Krasensky J, Havrdova E, Horakova D.

Mult Scler. 2016 Nov;22(13):1709-1718. Epub 2016 Feb 16.

PMID:
26883943

Supplemental Content

Loading ...
Support Center